Summary
Since 2012 the interest to the studies of the tear film lipid layer (TFLL) stabilizing the air/tear surface has dramatically raised. Firstly TFLL related abnormalities may be the main reason for dry eye syndrome (DES), the most prevalent ophthalmic public health disease affecting the quality of life of 10-30% of the human population worldwide and resulting in > €3.5 billion annual cost for EU. Secondly due to TFLL exceptionally slow turnover rate of 0.93 (±0.36)%/min, ophthalmic nanoemulsions mixing favorably with it can gain long residence at the ocular surface allowing for new routes of treatment not only of DES but also of glaucoma, the major vision threatening disease today. Therefore it is important to study the impact of key lipid classes to the micro- and nano-scale structure and to the dynamic surface properties of TFLL films at the air/water interface in health and disease and in vitro and vivo. This is what we will do by employing state of the art Langmuir surface balance, dilatational rheology, fluorescence and Brewster angle microscopy techniques as well as pharmacokinetic methodologies. The action will deliver both, (i) fundamental knowledge on TFLL functionality and DES mechanisms and (ii) molecules and formulations that can enhance TFLL functionality and lead to new therapies. The action will allow to European science and industry to aim for leadership in a field of increasing social importance.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/839315 |
| Start date: | 06-01-2020 |
| End date: | 05-01-2022 |
| Total budget - Public funding: | 159 815,04 Euro - 159 815,00 Euro |
Cordis data
Original description
Since 2012 the interest to the studies of the tear film lipid layer (TFLL) stabilizing the air/tear surface has dramatically raised. Firstly TFLL related abnormalities may be the main reason for dry eye syndrome (DES), the most prevalent ophthalmic public health disease affecting the quality of life of 10-30% of the human population worldwide and resulting in > €3.5 billion annual cost for EU. Secondly due to TFLL exceptionally slow turnover rate of 0.93 (±0.36)%/min, ophthalmic nanoemulsions mixing favorably with it can gain long residence at the ocular surface allowing for new routes of treatment not only of DES but also of glaucoma, the major vision threatening disease today. Therefore it is important to study the impact of key lipid classes to the micro- and nano-scale structure and to the dynamic surface properties of TFLL films at the air/water interface in health and disease and in vitro and vivo. This is what we will do by employing state of the art Langmuir surface balance, dilatational rheology, fluorescence and Brewster angle microscopy techniques as well as pharmacokinetic methodologies. The action will deliver both, (i) fundamental knowledge on TFLL functionality and DES mechanisms and (ii) molecules and formulations that can enhance TFLL functionality and lead to new therapies. The action will allow to European science and industry to aim for leadership in a field of increasing social importance.Status
CLOSEDCall topic
MSCA-IF-2018Update Date
28-04-2024
Images
No images available.
Geographical location(s)
